

0300

JAN 21 2004

**TRANSMITTAL LETTER  
(General - Patent Pending)**

Docket No.  
85761-28

In Application Of: **DUBOIS, Claire**

Serial No. 09/885,914	Filing Date June 22, 2001	Examiner Not assigned	Group Art Unit 1614
--------------------------	------------------------------	--------------------------	------------------------

Title: **USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT OF  
INFLAMMATORY OR MATRIX REMODELLING DISEASES**

TO THE DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE:

Transmitted herewith is:

1. Associate Power of Attorney or Agent (37 CFR 1.34);
2. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
3. Amendment and Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
4. 2 pages of Sequence Listing; 5. Diskette containing computer-readable copy of Sequence Listing.

- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-2550** as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

  
Signature

Dated: **January 20, 2004**

**S. Serge Shahinian, Reg. No. 52,533  
SMART & BIGGAR  
1000 de la Gauchetière Street West  
Suite 3400  
Montreal, Quebec  
H3B 4W5  
CANADA**

I certify that this document and fee is being deposited on \_\_\_\_\_ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

*Signature of Person Mailing Correspondence*

*Typed or Printed Name of Person Mailing Correspondence*

CC:



**Associate Power Of Attorney Or Agent (37 CFR 1.34)  
(For Representation Related To A Patent Application)**

Docket No.  
**85761-28**

In the Application Of: **DUBOIS, Claire**

Serial No.  
**09/885,914**

Filing Date  
**June 22, 2001**

Examiner  
**Not assigned**

Group Art Unit  
**1614**

Invention: **USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT  
OF INFLAMMATORY OR MATRIX REMODELLING DISEASES**

**TO THE COMMISSIONER FOR PATENTS:**

Please recognize the following as ☐ Associate Attorney ☒ Associate Agent in this application.

Name: **S. Serge Shahinian**

Reg. No.: **52,533**

Address: **SMART & BIGGAR  
1000 de la Gauchetière Street West  
Suite 3400  
Montreal, Quebec  
H3B 4W5  
CANADA**

Tel. No. **(514) 954-1500**

  
*Signature of Principal Attorney or Agent of Record*

Dated: **January 8, 2004**

**Stephan P. Georgiev, Reg. No. 37,563  
SMART & BIGGAR  
1000 de la Gauchetière Street West  
Suite 3400  
Montreal, Quebec  
H3B 4W5  
CANADA**

*Registration Number & Address of Principal Attorney or Agent of Record*

I certify that this document is being deposited on  
with the U.S. Postal Service as first  
class mail under 37 C.F.R. 1.8 and is addressed to the  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA  
22313-1450.

*Signature of Person Mailing Correspondence*

*Typed or Printed Name of Person Mailing Correspondence*




## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/885,914	06/22/2001	Claire Dubois	85761-28

Stephen P. Georgiev  
 SMART & BIGGAR  
 Suite 3400  
 1000 de la Gauchetiere Street West  
 Montreal, QC H3B 4W5  
 CANADA



CONFIRMATION NO. 5893

## FORMALITIES LETTER



\*OC000000011349281\*

Date Mailed: 11/24/2003

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in dark ink, appearing to be 'AB' or similar, is written above a horizontal line.

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE